In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:
The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.
Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.
The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.
What makes Finland and the Nordic region so special?
Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.